Why dismissal needs to stop
*Trigger warning: this article discusses distressing topics of suicide, trauma and abuse*
A recently published systematic review assessing 2.6 million people confirmed what many in this community already know. PMDD is linked to dramatically higher rates of suicide. Yet not a single study in that review evaluated treatments specifically targeting suicidality in PMDD.
The study
This landmark systematic review is the first of its kind and was published last month. It included 18 studies assessing suicidality in people with PMDD. Every single study produced evidence of heightened suicidality.
The numbers are stark:
General suicidality: 16-30% of people with PMDD
Suicidal ideation: 26-86%
Suicide planning: 11.5-41.5%
Suicide attempts: 7.1-60.7%
Completed suicide: 2x higher than those without premenstrual disorders
This isn't a mood disorder that makes life difficult. This is a condition that is life threatening and should be treated as a medical emergency, yet too often, those suffering are dismissed and cannot obtain proper support. .
So why then, is PMDD Awareness suicide prevention?
When a doctor dismisses cyclical mood symptoms as stress, anxiety, or “just hormones” - they miss a diagnosis that could save a life.
When a person spends years being told they’re too sensitive, too dramatic, too difficult - they internalise it. And in their darkest moments, they have no framework to understand why this is happening, or that it will pass when their luteal phase does.
Right now, the medical system is failing people with PMDD. Until that changes, the most powerful tool we have is awareness itself.
1. Every person who recognises and understands their symptoms is a potential life saved.
2. Every doctor who takes it seriously is a potential life saved.
3. Every social media post or story shared or article written about PMDD that reaches someone in their luteal phase who didn’t know this had a name - is a potential life saved.
Understanding who with PMDD is most at risk
Twelve of the 18 studies identified specific risk factors that push vulnerability even higher.
◉ Psychiatric comorbidity
Major depressive disorder (MDD), bipolar disorder, panic disorder, agoraphobia and other anxiety disorders strongly increased the risk of suicidal outcomes. MDD in particular was positively associated with increases across every measure: ideation, planning, and attempts.
◉ Hormonal triggers
This is the part that matters most neurobiologically. Studies identified that the sharp drop in estrogen and progesterone during the premenstrual phase directly triggers increases in suicidal ideation and planning, through steroid withdrawal and a surge in inflammatory cytokines.
One study proved how critical these hormonal drops are by testing a hormonal intervention. They found that providing participants with estradiol (E2) and progesterone (P4) starting seven days into the menstrual cycle prevented the sharp drop in hormones and successfully prevented an increase in suicide planning.
◉ Specific traits
Individuals who scored highly on traits like sensitivity to social rejection, perceived burdensomeness, hopelessness, worthlessness, and guilt had a significantly higher risk of experiencing suicidal ideation.
High scores in impulsivity and hostility were heavily linked to a higher risk of actual suicide attempts. These aren't character flaws, but instead they are neurobiological responses to a system under chronic hormonal stress.
◉ Trauma and abuse
Psychological abuse, physical abuse, childhood sexual abuse, and neglect were linked to increased suicidal ideation. In people with PMDD who had a history of childhood abuse, suicide severity scores were significantly higher. A history of abuse or neglect also directly increased the likelihood of attempts.
One finding worth noting: oral contraceptive use was associated with less several suicidality measures across the data suggesting a possible protective effect, though it’s known that effects vary between different people with PMDD and this requires further investigation before conclusions can be drawn.
The treatment gap
Of the 18 studies reviewed, not one evaluated a treatment specifically targeting suicidality in PMDD.
The medical treatments we currently use for PMDD were never designed with PMDD in mind. They were borrowed from other conditions - depression, contraception, hormone suppression - and happen to help a proportion of people with PMDD symptoms. But none of them were developed by asking "why does PMDD cause suicidal thoughts, and how do we stop that?"
For a disorder affecting millions - this is a failure of medical research.
What needs to change
1. PMDD must be treated as a medical emergency.
As PMDD is female specific, recognition in treatment and research is faced with a misogynistic lens, which creates a gap in care.
2. Suicide screening should be standard in PMDD care.
Given the prevalence figures above, every clinician working with PMDD patients should be asking about suicidality routinely not only in crisis moments.
3. Research must urgently target suicidality in PMDD specifically.
Current treatment options are limited to antidepressants or oral contraceptives - when PMDD has a different neurobiological mechanism behind it. We need effective treatment for those facing suicidality with PMDD.
4. High-risk groups need prioritised support
People with PMDD plus comorbid psychiatric conditions, particularly MDD, are at the highest risk. Integrated care pathways that treat both simultaneously don't yet exist in most healthcare systems.
Spreading awareness for PMDD is not just advocacy. It is, directly and literally, suicide prevention.
The paper:
Zhitnik, E., Britt, T., Bertone-Johnson, E. et al. Prevalence, Risk Factors, and Treatments for Suicidality in People Living with Premenstrual Dysphoric Disorder (PMDD): A Systematic Review. Adm Policy Ment Health (2026). https://doi.org/10.1007/s10488-026-01504-y
